A multicenter, investigator-blinded, randomized, controlled, parallel-group interventional exploratory phase IV trial to evaluate the effect of virtual reality enhanced patient education on illness perception, beliefs about medicines, adherence and disease activity in rheumatoid arthritis – the VIABLE-RA study

A multicenter, investigator-blinded, randomized, controlled, parallel-group interventional exploratory phase IV trial to evaluate the effect of virtual reality enhanced patient education on illness perception, beliefs about medicines, adherence and disease activity in rheumatoid arthritis – the VIABLE-RA study - VIABLE-RA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00021511

Enrollment

Registered

2021-09-20

Start date

2022-02-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M06.00 M05.80

Interventions

Group 1: Patients receiving an education about their disease (rheumatoid arthritis) using virtual reality Group 2: Patients receiving an oral education using powerpoint slides about their disease (rh

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: patients with rheumatoid arthritis

Exclusion criteria

Exclusion criteria: neurological disorder disorder/disease of ears, eyes, brain traumata head / ears vertigo

Design outcomes

Primary

Measure	Time frame
Illness Perception	—

Secondary

Measure	Time frame
Secondary objectives: to evaluate the effect of virtual reality enhanced education on - disease specific knowledge - beliefs about medicines - disease activity Tertiary objective: to collect data on acceptance of virtual reality and feasibility of a trial using virtual reality in patients with rheumatoid arthritis	—

Countries

Germany

Contacts

Public ContactPhilipp Klemm

Campus Kerckhoff der Justus Liebig Universität Giessen, Abt. für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin

p.klemm@kerckhoff-klinik.de06032-996-2101

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026